Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 1/20 | 0.56 |
| ▸ | PELP1 | Q8IZL8 | 1/20 | 0.56 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | ERN1 | O75460 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MYC | P01106 | 1/20 | 0.44 |
| ▸ | MAX | P61244 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30669433 | 1.00 | AR (0.56) | ARPELP1VCAM1KDM4EERN1 | |
| SCHEMBL7639896 | 0.90 | ALDH1A1 (0.54) | ARPELP1VCAM1KDM4EERN1 | |
| SCHEMBL8788640 | 0.88 | AR (0.44) | ARPELP1KDM4EPOLBRAB9A | |
| SCHEMBL23611055 | 0.86 | AR (0.55) | ARPELP1VCAM1ERN1POLB | |
| SCHEMBL221362 | 0.84 | AR (0.61) | ARPELP1VCAM1POLBRAB9A | |
| SCHEMBL10318922 | 0.83 | AR (0.57) | ARPELP1VCAM1ALDH1A1HPGD | |
| SCHEMBL30669432 | 0.83 | AR (0.57) | ARPELP1VCAM1ALDH1A1HPGD | |
| SCHEMBL30432735 | 0.83 | AR (0.60) | ARPELP1VCAM1POLBRAB9A | |
| SCHEMBL25227074 | 0.83 | AR (0.60) | ARPELP1VCAM1POLBRAB9A | |
| SCHEMBL7567974 | 0.82 | MAPT (0.43) | ARPELP1VCAM1KDM4EERN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117105916-B | Benzofuran compound and medical application thereof | 希格生科（深圳）有限公司 | 2024-01-16 | — | — | CN | disclosed |
| CN-117105916-A | Benzofuran compound and medical application thereof | 希格生科（深圳）有限公司 | 2023-11-24 | — | — | CN | disclosed |
| EP-2481739-B1 | DIHYDROPTERIDINONE DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF | JIANGSU HANSOH PHARMACEUTICAL CO LTD (CN) | 2016-12-14 | — | — | EP | disclosed |
| EP-2481739-B1 | DIHYDROPTERIDINONE DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF | JIANGSU HANSOH PHARMACEUTICAL CO LTD (CN) | 2016-12-14 | — | — | EP | disclosed |
| US-8691822-B2 | Dihydropteridinone derivatives, preparation process and pharmaceutical use thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2014-04-08 | — | — | US | disclosed |
| US-8691822-B2 | Dihydropteridinone derivatives, preparation process and pharmaceutical use thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2014-04-08 | — | — | US | disclosed |
| EP-2481739-A1 | DIHYDROPTERIDINONE DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF | Jiangsu Hengrui Medicine Co., Ltd. (CN) | 2012-08-01 | — | — | EP | disclosed |
| EP-2481739-A1 | DIHYDROPTERIDINONE DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF | Jiangsu Hengrui Medicine Co., Ltd. (CN) | 2012-08-01 | — | — | EP | disclosed |
| US-20120184543-A1 | DIHYDROPTERIDINONE DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2012-07-19 | — | — | US | disclosed |
| US-20120184543-A1 | DIHYDROPTERIDINONE DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2012-07-19 | — | — | US | disclosed |
| US-20120184543-A1 | DIHYDROPTERIDINONE DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2012-07-19 | — | — | US | disclosed |
| CN-102421778-A | Dihydropteridinone derivatives, preparation process and pharmaceutical use thereof | JIANGSU HENGRUI MEDICINE CO | 2012-04-18 | — | — | CN | disclosed |
| US-7407980-B2 | Imidazolinylmethyl aralkylsulfonamides | ROCHE PALO ALTO LLC (US) | 2008-08-05 | — | — | US | disclosed |
| US-7407980-B2 | Imidazolinylmethyl aralkylsulfonamides | ROCHE PALO ALTO LLC (US) | 2008-08-05 | — | — | US | disclosed |
| EP-1501817-A1 | IMIDAZOLINYLMETHYL ARALKYLSULFONAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-02-02 | — | — | EP | disclosed |
| US-20040214875-A1 | Imidazolinylmethyl aralkylsulfonamides | ROCHE PALO ALTO LLC | 2004-10-28 | — | — | US | disclosed |
| US-6756395-B2 | CYCLIZATION OF N-(4-CYANOMETHYLPHENYL)METHANESULFONAMIDES WITH ETHYLENEDIAMINE TO FORM N-(4-IMIDAZOL-2-YLMETHYL)-PHENYL) -METHANESULFONAMIDES; INCONTINENCE, SEXUAL DYSFUNCTION, NASAL CONGESTION, AND CNS DISORDERS; ALPHA 1 ADRENERGIC AGONISTS | ROCHE PALO ALTO LLC | 2004-06-29 | — | — | US | disclosed |
| US-20030229130-A1 | IMIDAZOLINYLMETHYL ARALKYLSULFONAMIDES | ROCHE PALO ALTO LLC. | 2003-12-11 | — | — | US | disclosed |
| WO-2003091236-A1 | IMIDAZOLINYLMETHYL ARALKYLSULFONAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040214875-A1 | Imidazolinylmethyl aralkylsulfonamides | RPS6KA1, RPS6KB1, RPS6KA6 | AR 2423/4885PELP1 3496/4885VCAM1 3970/4885 |
| US-20030229130-A1 | IMIDAZOLINYLMETHYL ARALKYLSULFONAMIDES | RPS6KA1, RPS6KB1, RPS6KA6 | AR 2423/4885PELP1 3496/4885VCAM1 3970/4885 |
| US-20120184543-A1 | DIHYDROPTERIDINONE DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF | PLK2, PLK3, DMPK | AR 1984/4885PELP1 869/4885VCAM1 3239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.